TEVA PHARMACEUTICAL INDUSTRIES LTD
For the period ended Dec 31, 2025. Filed Feb 3, 2026.
View on SEC.govAbout this filing
A company's yearly report to the SEC, with audited financial statements. It is the fullest account a company gives of its business, its finances and the risks it sees.
FY2025 · Filed Feb 3, 2026
Extracted filing text, with the paragraph anchors used by the comparison.
See the whole filing, with its images and exhibitsContents
Item 9B. Other Information
Director and Officer Rule
10b5-1
Trading Arrangements
During the three months ended December 31, 2025, each of the following officers
adopted
a Rule
10b5-1
trading arrangement (as such term is defined in Item 408 of Regulation
S-K).
All trading plans are intended to satisfy the affirmative defense of Rule
10b5-1(c)
under the Exchange Act.
| Name and Title | Date | Expiration Date | Maximum SharesSubject to Plan (1) |
|---|---|---|---|
| Evan Lippman, EVP, Business Development | November 10, 2025 | May 15, 2026 | 85,849 |
| Richard Daniell, EVP, Head of European Commercial | November 10, 2025 | March 6, 2026 | 244,186 |
| Dr. Eric Hughes, EVP, Global R&D and Chief Medical Officer | November 10, 2025 | August 4, 2026 | 231,217 |
| Placid Jover, EVP, Chief Human Resources Officer | November 10, 2025 | August 4, 2026 | 26,977 |
| Matthew Shields, EVP, Teva Global Operations | November 10, 2025 | June 4, 2026 | 33,490 |
| David R. McAvoy, EVP, Chief Legal Officer | November 10, 2025 | March 6, 2026 | 30,891 |
| Richard D. Francis, President and CEO | November 14, 2025 | June 8, 2026 | 1,570,667 |
| Eli Kalif, EVP, Chief Financial Officer | November 26, 2025 | June 12, 2026 | 605,624 |
| (1) | Certain plans include shares to be sold solely to cover tax withholding obligations. |
The text of this filing, as the company filed it with the SEC, without its images or exhibits. This is not investment advice.